Skip to main content

Advertisement

Table 4 Treatment and evolution “cure” in patients with loiasis: mono-therapy vs combined-therapy

From: Loiasis in sub-Saharan migrants living in Spain with emphasis of cases from Equatorial Guinea

 N (%)
(N = 102)
CureAdverse effectsSteroids
n (%)
(N = 44)
Anti-histaminic
n (%)
(N = 53)
n (%)
(N = 57)
P-value*
OR (95% CI)
n (%)
(N = 14)
P-value
Ivermectin58 (56.9)30 8 1937
 Ivermectin alone16 (15.7)0< 0.001* 3.5 (2.2–5.6)2/16 (12.5)0.8604/16 (25.0)7/16 (43.8)
 Ivermectin with other antihelminth(s)a42 (41.2)30/42 (71.4)6/42 (14.3)15/42 (35.7)30/42 (71.4)
Diethylcarbamazcine57 (55.9)50 10 3240
 Diethylcarbamazcine alone13 (12.7)9/13 (69.2)0.021*
6.0 (1.1–32.0)
2/13 (15.4)0.8169/13 (69.2)7/13 (53.8)
 Diethylcarbamazcine with other antihelminth(s)a44 (43.1)41/44 (93.2)8/44 (18.2)23/44 (52.3)33/44 (75.0)
Albendazole20 (19.6)13 3  9
 Albendazole8 (7.8)4/8 (50.0)0.251
3.0 (0.4–20.1)
1/8 (12.5)0.7985/8 (62.5)3/8 (37.5)
 Albendazole with other antihelminth(s)a12 (11.8)9/12 (75.0)2/12 (16.7)10/12 (83.3)6/12 (50.0)
Mebendazole43 (42.1)  5 1021
 Mebendazole alone9 (8.8)2/9 (22.2)0.022* 6.4 (1.1–35.9)00.22100
 Mebendazole with other antihelminth(s)a34 (33.3)22/34 (64.7)5/34 (14.7)10/34 (29.4)21/34 (61.8)
  1. *Statistical significance level of 5% (P < 0.05)
  2. aCombined therapy: Diethylcarbamazcine-Ivermectin-Mebendazole, Ivermectin-Albendazole-Mebendazole, Diethylcarbamazcine-Ivermectin, Diethylcarbamazcine-Albendazole, Diethylcarbamazcine-Mebendazole, Ivermectin-Mebendazole, or Albendazole-Mebendazole
  3. CI: Confidential interval; OR: Odds ratio